Advertisement
Advertisement
U.S. markets open in 5 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Fulgent Genetics, Inc. (FLGT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
52.72-7.14 (-11.93%)
At close: 04:00PM EDT
53.49 +0.77 (+1.46%)
After hours: 07:56PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • M
    Mahdi
    Why is this hoing down? They had good earning and guidance!!!!
  • D
    Daniel C
    This stock is cheap in the 50s
  • S
    SHəˈzam
    Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox

    TEMPLE CITY, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Fulgent Genetics, Inc. (NASDAQ: FLGT) today announced it has launched a test for monkeypox that leverages the U.S. Centers for Disease Control and Prevention’s (CDC) orthopoxvirus test, which detects non-smallpox related orthopoxviruses, including monkeypox. Fulgent will begin accepting specimens for testing next week from healthcare providers, clinics and state laboratories.

    “We are pleased to be able to offer PCR-based testing for monkeypox to help increase testing capacity for the virus, making it more convenient and accessible for patients and health care providers in the United States,” said Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. “While treatment and care for monkeypox is well established and understood, it is crucial that the public has access to proper testing resources to limit transmission and help manage the current outbreak of the virus in the U.S. While demand for the test will be hard to predict, the efficiency of our technology platform and lab operations has enabled us to rapidly develop the test with minimal investment. We expect to be able to scale testing capacity for monkeypox rapidly and efficiently, as we did with testing for COVID-19 in early 2020.”
    Bullish
  • w
    wisdomnotinfo
    58% of the float is owned by institutions and the float is only 20 million shares. Can be tough to hold this stock sometimes.
  • T
    Tom
    The core businesses will lead the way. Holding. Once Wall Street realizes this is not just a covid stock we should see uptrend.
    This had to happen. Thought we were finally on the up trend. Guess not. Good Luck to all!
  • Y
    Yaroslav
    whats wrong with this stock. instead of heating 150 it goes in the opposite direction.
  • w
    wisdomnotinfo
    As I understand the Q1 report, if they hit guidance for Q2, PE without COVID revenue would be about 36.
  • S
    SHəˈzam
    The American Medical Association Approves a New Category I CPT Code for Fulgent Genetic's HelioLiver Test
    (article available on businesswire)

    "
    July 5, 2022 /PRNewswire/ -- Helio Genomics ("Helio"), and its commercial partner, Fulgent Genetics (NASDAQ: FLGT) ("Fulgent") announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022.

    The provision of a CPT PLA code and expected subsequent Medicare reimbursement facilitates the seamless integration of HelioLiver into the American healthcare system, validating Helio's values-based approach to early liver cancer detection for at-risk patients and elevating the standard of care.

    The CPT PLA code for HelioLiver will allow providers to efficiently conduct routine surveillance of at-risk patients and streamline the reporting of services, claims processing and development of guidelines for medical care review, ultimately advancing more sophisticated and comprehensive care for patients.
    "
  • G
    G M
    Needs to come down a bit. To expensive without the covid testing revs and profit
  • R
    Rahi
    Asking to experts!!!
    FLGT has very low P/E ratio. So basically it should be stable in market rather then just going down and down.
    May i know the reason for it?
  • F
    Francisco
    Added to my position. These prices are too good to ignore.
  • u
    unstable genius
    check out Siga

    working oral treatment for monkey pox
    Canada just bought 28 million worth of drug
    Senators asking FDA to EUA the drug due to LGBTA communities spread
    2-3k new infections a week worldwide
  • w
    wisdomnotinfo
    Any company that acquires FLGT gets a half billion in cash and positive cash flow for the foreseeable future.
  • T
    Thomas
    Another $10K in. will be sitting pretty after Q2 report! Lets Goooooo!
    Bullish
  • A
    AJ111
    Great report! FLGT is a screaming buy at this point. And here is WHY:

    Firstly, ... So... I was right! :)- At the end of February and then in March I posted here and said the following:

    1) $100 million revenue in 2021 for non-covid testing (while they ahd forecasted $70 million)
    2) I said Share price would be cut to low/mid $70s or a market cap at around $2-$2.5 Billion.
    3) I also said Majority of revenue from covid-testing would be in Q1 and dropping sequentially.
    4) And I said BANK ON FLGT's Great management team.

    SO now that the earnings report is out based on above where the stock will be at the end of this year?

    Discount everything that has to do with covid-testing and consider the $730 million revenue as just one time booking. So we are left with $100 million in non covid testing.

    1. In my view FLGTwill do $125-$135 million in non-covid testing (probably more but I do think it will be $125-$130 million for sure). THis is based on what we see with all other precision medicine companies and the rate of demand and growth. Also they said on the CC The NGS revenues for Q1 a little less than $16 million and less than $1 million of that came from the CDC. This implies as covid testin revenue is going to drop sequentially, the NGS revenue is going to increase sequentially.

    2. The question becomes how much of this $100 million revenue translates into actual earnings. The projection is $380 million profit based on $830 million revenue. So if we do the simple math of taking the percentage of non-covid vs. covid, i.e. $100/$830 = 12%, and if we assume 12% of the $380 million profit is attributed to non-covid then we are left with $45 million profit from $100 million non-covid testing.

    This makes the P/E (based on market cap of $2.1 Billion as of today Thursday May 6, 2021) to be about $2.1 billion market cap divided by $45 M = appx. 46.

    So now lets see with PEG (Price to earnings ratio to earnings growth is). The earning growth as a whole is almost at 78% ($380 in 2021 vs. $$214.3). This is also true for non covid testing earnings growth YoY (at the minimum). Thus making PEG = 46/78 = 0.59

    PEG = 1 >>>> stock is fairly valued.
    PEG < 1 >>>> stock is undervalue
    PEG > 1 >>>>> stock is overvalued.

    Clearly PEG being at 0.59 (strictly from NGS) implies at a market cap of $2.1 billion, the stock is VERY CHEAP and a SCREAMING BUY.

    For PEG to be at 1, market cap needs to raise to $3.5Billion (thus making P/E to be at 78 and hence PEG = 1).

    And based on 30 million outstanding shares, it would mean a fair value for FLGT stock is at around $120. This is strictly based on their core business of genetic testing which the market would consider (the covid testing is viewed as one time temporary revenue).

    As such FLGT is a screaming buy with the target price of $120 per share.

    Best wishes to all
  • M
    Maria
    Fourth Quarter 2020 Results:

    Record Revenue of $295.0 million, growing more than 3,400% year-over-year

    Record Billable tests delivered approximately 3.2 million, approximately 230 times the volume of fourth quarter of 2019

    Gross Margin improved over 8 percentage points sequentially and approximately 26 percentage points year-over-year; cost per test improved approximately 36% sequentially

    Non-COVID Revenue grew 43% year-over-year

    Record GAAP income of $166.3 million, or $6.16 per share

    Record Non-GAAP income of $167.5 million, or $6.20 per share

    Record Adjusted EBITDA of $230.1 million

    2021 Outlook:

    Expects overall revenue of approximately $800.0 million in 2021, representing growth of 90% year-over-year

    Of the $800.0 million, anticipates $70.0 million in revenue from NGS testing, representing growth of 92% year-over-year

    Expects GAAP income of approximately $12.00 per share; non-GAAP income of approximately $12.50 per share in 2021

    TEMPLE CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing large-scale COVID-19 testing services and comprehensive testing solutions through its scalable technology platform, today announced financial results for its fourth quarter and full year ended December 31, 2020.
    Fourth quarter revenue was $295.0 million, an increase of 3,400% from $8.4 million in the fourth quarter of 2019. GAAP income for the fourth quarter of 2020 was $166.3 million, or $6.16 per share, and non-GAAP income was $167.5 million, or $6.20 per share.
    Full year 2020 revenue was $421.7 million, an increase of 1,200% from $32.5 million in 2019. GAAP income for the full year 2020 was $214.3 million, or $8.91 per share, and non-GAAP income was $218.9 million, or $9.10 per share.
    Adjusted EBITDA was $230.1 million in the fourth quarter of 2020, compared to $1.1 million in the fourth quarter of 2019. Adjusted EBITDA was $301.3 million in the full year 2020, compared to $4.9 million in 2019.
  • D
    Delta
    After the upgrade, the four analysts covering Fulgent Genetics are now predicting revenues of US$523m in 2021. If met, this would reflect a major 287% improvement in sales compared to the last 12 months. Statutory earnings per share are presumed to surge 348% to US$10.04. Before this latest update, the analysts had been forecasting revenues of US$369m and earnings per share (EPS) of US$6.16 in 2021. So we can see there's been a pretty clear increase in analyst sentiment in recent times, with both revenues and earnings per share receiving a decent lift in the latest estimates. THIS is INCREDIBLE GROWTH, Extremely rare for any company to do this.
    Bullish
  • A
    AJ111
    Fellow FLGT longs... this is what I posted 27 days ago when the earnings report came out, and I still say it now and again repeating it...
    Discount everything that has to do with covid-testing and consider the $730 million revenue as just one time booking. So we are left with $100 million in non covid testing.

    1. In my view FLGTwill do $125-$135 million in non-covid testing (probably more but I do think it will be $125-$130 million for sure). Also they said on the CC The NGS revenues for Q1 was be a little less than $16 million and less than $1 million of that came from the CDC. This implies that covid testing revenue is going to drop sequentially, and the NGS revenue is going to increase sequentially.

    2. The question becomes how much of this $100 million revenue translates into actual earnings. The projection is $380 million profit based on $830 million revenue. So if we do the simple math of taking the percentage of non-covid vs. covid, i.e. $100/$830 = 12%, and if we assume 12% of the $380 million profit is attributed to non-covid then we are left with $45 million profit from $100 million non-covid testing.

    This makes the P/E (based on market cap of $2.1 Billion as of today Thursday May 6, 2021) to be about $2.1 billion market cap divided by $45 M = appx. 46.

    So now lets see with PEG (Price to earnings ratio to earnings growth is). The earning growth as a whole is almost at 78% ($380 in 2021 vs. $$214.3). This is also true for non covid testing earnings growth YoY (at the minimum). Thus making PEG = 46/78 = 0.59

    PEG = 1 >>>> stock is fairly valued.
    PEG < 1 >>>> stock is undervalue
    PEG > 1 >>>>> stock is overvalued.

    Clearly PEG being at 0.59 (strictly from NGS) implies at a market cap of $2.1 billion (or a stock price of $75 as of close of market June 2, 2021), the stock is VERY CHEAP and a SCREAMING BUY.

    Now if you are hard nose bargain hunter, the stock will be volatile (thanks to our shortsighted short seller friends whose ego is bruised and hence continue to be in denials) and hence you can probably still buy the stock in the mid to high $60's (anything below $80 is simply a SCREAMING SCREAMING buy).

    Why?

    For PEG to be at 1, market cap needs to raise to $3.5Billion (thus making P/E to be at 78 and hence PEG = 1).

    And based on 30 million outstanding shares, it would mean a fair value for FLGT stock is at around $120. This is strictly based on their core business of genetic testing which the market would consider for its valuation model (to repeat the covid testing is viewed as just one time temporary revenue and no one should bank on it).

    As such FLGT is a screaming buy with the target price of $120 per share based on its current PEG value of 0.59).

    Best wishes to all
Advertisement
Advertisement